HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Faster and More Efficient Stem Cell Collection with FDA Approved APHEXDA
Posted: Sep 13, 2023
Faster and More Efficient Stem Cell Collection with FDA Approved APHEXDA image

The first innovation in stem cell mobilization for multiple myeloma was approved on September 11, 2023. BioLineRx announced the FDA approval of APHEXDA (motixafortide) in combination with Filgrastim (G-CSF) to mobilize stem cells for autologous stem cell transplants of multiple myeloma patients. 

This is exciting news for the myeloma community, as stem cell transplant is still the standard of care, and currently, about 47% of patients have had challenges collecting target numbers of hematopoietic stem cells for an autologous stem cell transplant after one apheresis session. 

Increased age, as well as exposure to REVLIMID (lenalidomide)-containing combination regimens have been associated with impaired stem cell transplant mobilization.

The newly approved APHEXDA improves stem cell mobilization significantly, with patients in the GENESIS clinical trial arm of APHEDA plus filgrastim (versus placebo and filgrastim) collecting more than four times the amount of stem cells with a single dose over a twenty-four-hour period. 

Patients in this trial were reflective of the myeloma population, with the median age of 63 and ~70% of the patients having received a lenalidomide-containing regimen previous to their stem cell transplant. 

Transplant specialists expect around three to five million cells to be collected during apheresis. While that number sounds astronomical, that's the number of stem cells it takes to complete two successful stem cell transplants. 

APHEXDA is a subcutaneous injection, making it easy for myeloma patients to receive. That being said, some of the common side effects during the clinical trial were: 

  • vomiting 
  • injection site reaction (pain, erythema, and pruritus)
  • flushing
  • back pain 
  • hypokalemia 
  • hypoxia 

The list above is not comprehensive, please discuss with your healthcare team about potential side effects before receiving APHEXDA. 

Dr. John DiPersio, MD, PhD, the primary investigator for the GENESIS trial says,

"Innovation in this area of medicine has been needed...[APHEXDA] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization versus filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with [multiple myeloma]." 

For those who choose to have a stem cell transplant as part of their myeloma care, this newly approved injection will improve stem cell collection time and efficiency. It's an exciting time of improvement and progress in the myeloma treatment world! 


To learn more about Stem Cell Transplant, check out our HealthTree resources below: 

The author Audrey Burton-Bethke

about the author
Audrey Burton-Bethke

Audrey is the Editor for the HealthTree Foundation for Multiple Myeloma. She originally joined the HealthTree Foundation in 2020 as the Myeloma Community Program Director. While not knowing much about myeloma initially, she worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys iced chais from Dutch Bros. She also loves spending time with her supportive husband and energetic three-year-old. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube